Literature DB >> 23777766

Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models.

Mingqiang Ren1, Haiyan Qin, Eiko Kitamura, John K Cowell.   

Abstract

Myeloid and lymphoid neoplasm associated with FGFR1 is an aggressive disease, and resistant to all the current chemotherapies. To define the molecular etiology of this disease, we have developed murine models of this disease, in syngeneic hosts as well as in nonobese diabetic/severe combined immunodeficiency/interleukin 2Rγ(null) mice engrafted with transformed human CD34+ hematopoietic stem/progenitor cells. Both murine models mimic the human disease with splenohepatomegaly, hypercellular bone marrow, and myeloproliferative neoplasms that progresses to acute myeloid leukemia. Molecular genetic analyses of these model mice, as well as primary human disease, demonstrated that CNTRL-FGFR1, through abnormal activation of several signaling pathways related to development and differentiation of both myeloid and T-lymphoid cells, contribute to overt leukemogenesis. Clonal evolution analysis indicates that myeloid related neoplasms arise from common myeloid precursor cells that retain potential for T-lymphoid differentiation. These data indicate that simultaneously targeting these pathways is essential to successfully treating this almost invariably lethal disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23777766      PMCID: PMC3739028          DOI: 10.1182/blood-2013-03-489823

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

Review 1.  Redefinition of lymphoid progenitors.

Authors:  Yoshimoto Katsura
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

2.  A lineage switch from AML to ALL with persistent translocation t(4;11) in congenital leukemia.

Authors:  Maryna Krawczuk-Rybak; Janusz Zak; Barbara Jaworowska
Journal:  Med Pediatr Oncol       Date:  2003-07

3.  Lymphoid development in mice congenitally lacking T cell receptor alpha beta-expressing cells.

Authors:  K L Philpott; J L Viney; G Kay; S Rastan; E M Gardiner; S Chae; A C Hayday; M J Owen
Journal:  Science       Date:  1992-06-05       Impact factor: 47.728

4.  The common myelolymphoid progenitor: a key intermediate stage in hemopoiesis generating T and B cells.

Authors:  Min Lu; Hiroshi Kawamoto; Yoshihiro Katsube; Tomokatsu Ikawa; Yoshimoto Katsura
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

Review 5.  Transcription control of early B cell differentiation.

Authors:  Elizabeth M Mandel; Rudolf Grosschedl
Journal:  Curr Opin Immunol       Date:  2010-02-09       Impact factor: 7.486

Review 6.  The proto-oncogene c-myc in hematopoietic development and leukemogenesis.

Authors:  Barbara Hoffman; Arshad Amanullah; Marianna Shafarenko; Dan A Liebermann
Journal:  Oncogene       Date:  2002-05-13       Impact factor: 9.867

7.  Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency.

Authors:  D A Williams; W Tao; F Yang; C Kim; Y Gu; P Mansfield; J E Levine; B Petryniak; C W Derrow; C Harris; B Jia; Y Zheng; D R Ambruso; J B Lowe; S J Atkinson; M C Dinauer; L Boxer
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

8.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

9.  Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.

Authors:  Sergei Roumiantsev; Daniela S Krause; Carola A Neumann; Christopher A Dimitri; Frances Asiedu; Nicholas C P Cross; Richard A Van Etten
Journal:  Cancer Cell       Date:  2004-03       Impact factor: 31.743

Review 10.  The role of FLT3 in haematopoietic malignancies.

Authors:  Derek L Stirewalt; Jerald P Radich
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

View more
  18 in total

1.  FGFR1OP2-FGFR1 induced myeloid leukemia and T-cell lymphoma in a mouse model.

Authors:  Haiyan Qin; Qing Wu; John K Cowell; Mingqiang Ren
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

2.  FGFR1 Rearrangement Guides Diagnosis and Treatment of a Trilineage B, T, and Myeloid Mixed Phenotype Acute Leukemia.

Authors:  Ying Liu; Xiaoli Mi; Ramya Gadde; Qi Gao; Wenbin Xiao; Yanming Zhang; Rayma Benayed; Maria Arcila; Ahmet Dogan; Mark B Geyer; Mikhail Roshal
Journal:  JCO Precis Oncol       Date:  2020-08-25

3.  A model of BCR-FGFR1 driven human AML in immunocompromised mice.

Authors:  John K Cowell; Haiyan Qin; Chang-Sheng Chang; Eiko Kitamura; Mingqiang Ren
Journal:  Br J Haematol       Date:  2015-12-21       Impact factor: 6.998

4.  Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.

Authors:  John K Cowell; Haiyan Qin; Tianxiang Hu; Qing Wu; Aaron Bhole; Mingqiang Ren
Journal:  Int J Cancer       Date:  2017-07-28       Impact factor: 7.396

5.  Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice.

Authors:  Mingqiang Ren; Haiyan Qin; Qing Wu; Natasha M Savage; Tracy I George; John K Cowell
Journal:  Int J Cancer       Date:  2016-05-04       Impact factor: 7.396

6.  DNA methyltransferase 1-mediated CpG methylation of the miR-150-5p promoter contributes to fibroblast growth factor receptor 1-driven leukemogenesis.

Authors:  Tianxiang Hu; Yating Chong; Baohuan Cai; Yun Liu; Sumin Lu; John K Cowell
Journal:  J Biol Chem       Date:  2019-10-18       Impact factor: 5.157

7.  Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1.

Authors:  Shohei Yamamoto; Makoto Otsu; Emiko Matsuzaka; Chieko Konishi; Haruna Takagi; Sachiyo Hanada; Shinji Mochizuki; Hiromitsu Nakauchi; Kohzoh Imai; Kohichiro Tsuji; Yasuhiro Ebihara
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

Review 8.  FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).

Authors:  Masaru Katoh
Journal:  Int J Mol Med       Date:  2016-05-31       Impact factor: 4.101

9.  SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models.

Authors:  Qing Wu; Aaron Bhole; Haiyan Qin; Judith Karp; Sami Malek; John K Cowell; Mingqiang Ren
Journal:  Oncotarget       Date:  2016-08-02

10.  Transformation of human CD34+ hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model.

Authors:  H Qin; S Malek; J K Cowell; M Ren
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.